Shares of Metsera, Inc. (NASDAQ:MTSR - Get Free Report) rose 7.6% during mid-day trading on Monday . The company traded as high as $29.20 and last traded at $28.76. Approximately 440,584 shares traded hands during trading, a decline of 50% from the average daily volume of 880,980 shares. The stock had previously closed at $26.72.
Wall Street Analysts Forecast Growth
MTSR has been the topic of several recent research reports. Guggenheim began coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued a "buy" rating and a $56.00 price target on the stock. Cantor Fitzgerald started coverage on shares of Metsera in a report on Tuesday, February 25th. They set an "overweight" rating for the company. Bank of America began coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued a "buy" rating and a $38.00 price objective on the stock. Finally, Evercore ISI started coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an "outperform" rating on the stock.
Get Our Latest Research Report on MTSR
Metsera Stock Performance
The company has a 50 day moving average of $22.87.
Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($1.03) earnings per share for the quarter.
Institutional Trading of Metsera
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Alphabet Inc. bought a new position in shares of Metsera during the first quarter worth $135,059,000. T. Rowe Price Investment Management Inc. bought a new stake in shares of Metsera in the 1st quarter worth about $78,748,000. Wellington Management Group LLP bought a new stake in shares of Metsera in the 1st quarter worth about $65,382,000. Alpha Wave Global LP purchased a new position in Metsera in the 1st quarter worth about $64,894,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in Metsera in the 1st quarter worth about $42,395,000.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
